Saturday, May 25, 2013 Last update: Yesterday, 10:04 PM
Company Tech News as it Breaks
Amarantus Bioscience, Inc.
News articles for Amarantus Bioscience, Inc.:
Friday, April 5, 2013
- Amarantus BioScience to Hold Business Update Conference Call on April 16Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will ... read more
Thursday, April 4, 2013
- Amarantus BioScience Modifies Business Structure to Support Product Development StrategyAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will ... read more
Tuesday, April 2, 2013
- Amarantus BioScience Appoints Adam J. Simon, Ph.D., to Board of AdvisorsAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has appointed Adam J. ... read more
Wednesday, March 27, 2013
- Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson’s DiseaseAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive ... read more
Wednesday, March 20, 2013
- Amarantus BioScience Obtains Cessation of Unauthorized Listing on Berlin-Bremen Stock ExchangeAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its ... read more
Monday, March 18, 2013
- Amarantus BioScience Appoints Mark Benedyk, Ph.D., to Board of DirectorsAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its ... read more
Tuesday, March 5, 2013
- Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness ConferenceAmarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis ... read more
Monday, February 25, 2013
- Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury ConferenceSUNNYVALE, Calif. and ALACHUA, Fla., Feb. 25, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitro diagnostic ... read more
Friday, February 8, 2013
- Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor ConferenceSUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Gerald E. Commissiong, President and Chief Executive Officer ... read more
Wednesday, February 6, 2013
- OneMedPlace Research Releases Update to Research Report on Amarantus BioScienceSUNNYVALE, Calif., Feb. 6, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that OneMedPlace Research has released an update to its ... read more
Monday, February 4, 2013
- Amarantus BioScience Reports Statistical Significance Achieved for MANF Striatal Reinnervation in Neurorestoration Animal Model of Parkinson's DiseaseSUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today reported that upon further analysis of the data reported on January ... read more
Thursday, January 31, 2013
- Amarantus BioScience Secures an Additional $1.4 Million in Financing CommitmentsSUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of ... read more
Monday, January 28, 2013
- Amarantus BioScience Launches New WebsiteSUNNYVALE, Calif., Jan. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced the launch of the Company's new website at ... read more
Wednesday, January 16, 2013
- Amarantus BioScience Announces Publication of Independent Peer-Reviewed Data for Receptor and Secretion Pathways related to MANFSUNNYVALE, Calif., Jan. 16, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today announced that an independent peer-reviewed research paper ... read more
Thursday, January 10, 2013
- Amarantus BioScience Announces Biotech Showcase 2013 Corporate Presentation is Available OnlineSUNNYVALE, Calif., Jan. 10, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today announced that a corporate presentation made ... read more
Wednesday, January 9, 2013
- Amarantus BioScience Announces Positive Efficacy Data for MANF in a Nigral Delivery Neurorestoration Animal Model of Parkinson's DiseaseSUNNYVALE, Calif., Jan. 9, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today presented positive preclinical efficacy data for MANF in a ... read more
Tuesday, January 8, 2013
- Amarantus Bioscience Neurorestoration Animal Data Presentation to be Webcast Live Today from OneMedForum 2013 at 4:40pm EasternSUNNYVALE, Calif., Jan. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that Dr. John W. Commissiong, CSO will present results of its MANF Parkinson's disease neurorestoration animal studies ... read more
Thursday, December 27, 2012
- Amarantus BioScience to Present at Biotech Showcase 2013SUNNYVALE, Calif., Dec. 27, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong will make a corporate presentation ... read more
Wednesday, December 26, 2012
- Amarantus BioScience Acquires Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical ProductsSUNNYVALE, Calif., Dec. 26, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced the Company has purchased all of the intellectual property (IP) assets from Power3 Medical Products. Power3 was in bankruptcy, giving Amarantus ... read more
Thursday, December 20, 2012
- Amarantus Bioscience to Present Parkinson's Neurorestoration Animal Data Results at OneMedForumSUNNYVALE, Calif., Dec. 20, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that Dr. John W. Commissiong, CSO will present results of its Parkinson's disease neurorestoration animal studies at the ... read more